Overcoming cancer immune tolerance and escape.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 19188142.
- Also identified by DOI 10.1158/1078-0432.CCR-08-2805.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Although HER2/neu-targeted cancer vaccines have shown initial promise in the adjuvant setting, a therapeutic vaccine remains elusive due to the tumor escape mechanisms of established cancer. As described by Seavey et al. in this issue of CCR, a Listeria-delivered vaccine may help overcome immune tolerance, leading to an effective therapeutic vaccine.
Medical subject headings
- Immune Tolerance
- Listeria monocytogenes
- Neoplasms
- Tumor Escape